Why the study?
Does co-trimoxazole displace warfarin from plasma albumin and prolong prothrombin time in patients receiving warfarin?
Does co-trimoxazole displace warfarin from plasma albumin and prolong prothrombin time in patients receiving warfarin?
Co-trimoxazole can displace warfarin from plasma albumin in vitro, but clinically significant hypoprothrombinaemia is likely rare and primarily a risk for patients with high warfarin doses and low plasma albumin.
Answers are grounded in this paper and cite their sources.
Volunteer data show no prothrombin time change despite in vitro displacement; leaves open interaction risk in patients with low albumin or high warfarin doses.
A patient is described in whom there was strong circumstantial evidence of an interaction between warfarin and co-trimaxazole. To test the validity of this hypothesis a series of in vitro and in vivo human studies were untaken. The results indicate that interaction may occur in which the sulphamethoxazole moiety of co-trimoxazole displaces warfarin from its binding sites on plasma albumin. Nevertheless, this interaction occurs only at high plasma levels of warfarin and is most likely to be clinically significant only in patients receiving high doses of warfarin who have low plasma albumin concentrations. These studies indicate that the use of co-trimoxazole is not contra-indicated in patients receiving warfarin therapy, but care should be exercised, especially in patients with high plasma warfarin:albumin ratios.
No takes yet. Share an insight, caveat, or question.
Tilstone et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: